Raymond James Sees ‘Multiple Expansion’ To Drive Stock Market Returns – Here Are 2 Stocks To Play That Bullish Sentiment

It is time to get your crystal ball out and take a look at to determine what awaits the inventory market this 12 months. To this point, it is clear that shares are rebounding considerably from their 2022 lows, and one Wall Road knowledgeable says there may be extra runway for good points.

Writing in regards to the market state of affairs for 2023, Larry Adam, chief funding officer of Raymond James, notes that final 12 months was the second 12 months in a row for a number of leverage — however that state of affairs isn’t repeated for the third time. He expects a number of expansions to “drive inventory market returns” sooner or later. To wit: “Historical past means that our view of a light recession ending on the finish of the 12 months, easing of inflationary pressures, decrease rates of interest, and a much less aggressive Fed all recommend that ‘unhealthy information’ has been priced into multiples and units up a number of prospects within the 12 months. 2023.”

Adam acknowledges that earnings are more likely to decline this 12 months, however he is nonetheless concentrating on the tip of the 12 months Customary & Poor’s 500 at 4,400, or about 10% above present ranges. Supporting this place – with a number of expansionary components – Adam particularly cites the prospect of decrease inflation, with value will increase petering out to round 3%; a subsequent slowdown in rates of interest, as larger charges wouldn’t be wanted to fight rising charges; And the Fed switched to only two extra charge hikes, halting in March.

So, in Raymond James’s view, we must be in search of a greater funding setting that comes into play within the second half of this 12 months – and the corporate’s inventory analyst Andrew Cooper has picked two shares that he sees as poised for good points, and he recommends shopping for in now. Let’s take a better look.

Natera, Inc (The Nationwide Telecommunications Regulatory Authority)

We’ll begin with Natera, a biotechnology firm that is within the pipeline for cell-free DNA, or cfDNA, testing. CFDNA assessments are minimally invasive, primarily based on a easy blood draw, and concentrate on naturally occurring DNA fragments that float freely within the bloodstream. Natera’s expertise captures these components and makes use of them in genetic testing.

The corporate’s check platforms are primarily based on novel molecular biology strategies and AI-driven bioinformatics software program, and might detect single DNA molecules in a tube of blood pattern. Natera makes use of this expertise for correct, non-invasive prenatal testing (Panorama platform), tumour-specific screening check for particular person most cancers therapies (Signatera platform), and best-in-class rejection analysis check earlier than kidney transplantation (Prospira platform).

Diagnostic DNA testing is massive enterprise, and Natera is capitalizing on sufferers’ want for a much less invasive medical expertise. The corporate’s income has proven constant progress over the previous a number of years, and in its most not too long ago reported quarter, Q3 ’22, Natera noticed a prime line of $210.6 million, up 33% year-over-year. The income acquire got here on prime of a 27% improve in assessments processed throughout the third quarter of ’22, from 407,300 to 517,500. Of this whole, the oncology phase skilled the strongest progress. The corporate processed 53,000 oncology assessments within the quarter, up 153% year-over-year.

Natera revised its ahead steerage upward in its third-quarter report, projecting full-year 2022 revenues of $810 million to $830 million. This was $40 million larger on the midway level than beforehand printed steerage. The corporate is predicted to report This fall ’22 ends in late February, and we’ll discover out after that how the steerage holds up.

Becoming a member of the bulls, Raymond James’ Andrew Cooper is taking a bullish stance on this firm and its inventory.

“With each phase rising properly within the close to and medium time period and a catalyst-rich setup in 2023, significantly in oncology, we’re upgrading the inventory to Outperform. Management within the burgeoning MRD area, the place we imagine it may well win further protection and potential directive itemizing on The least for CRC generates pleasure, whereas the more and more profitable ladies’s well being firm has its personal catalysts within the dialog about 22q. All of it comes right down to an evaluation that appears, no less than on a relative foundation, to be moderately acceptable all issues thought-about.” mentioned the analyst.

The Cooper Outperform (i.e. Purchase) score on NTRA comes with a value goal of $58, indicating a one-year upside potential of 35%. (To observe Cooper’s log, click on right here)

Total, this attention-grabbing biotech has obtained 9 analyst opinions not too long ago, together with 8 Buys for 1 contract – for a Robust Purchase consensus score. Shares are buying and selling for $42.94 and a median value goal of $63 suggests an upside of round 47% for the subsequent 12 months. (We see Nationwide Telecommunications Regulatory Authority inventory forecast)

Fulgent Genetics, Inc. (FLGT)

Fulgent, Raymond James’ second decide we’re taking a look at, is a full-service genomic testing firm, with a concentrate on bettering affected person care within the areas of oncology, infectious and uncommon illnesses, and reproductive well being. The corporate operates proprietary expertise behind its testing platform, and has created a catalog of assessments that’s broad, versatile, and in a position to broaden with choices optimized because the genetic reference library grows.

This firm was based in 2011, and within the years since then it has constructed up a repute for high-quality genomic testing. The corporate supplies best-in-class assist providers for its testing platform, making certain the perfect outcomes for the perfect affected person care and outcomes.

In Q3 of ’22, the latest reported quarter, the corporate’s prime line was $105.7 million, lower than half of the $227.9 million reported in Q3 of ’21. The income drop should not be shocking, contemplating Billable assessments decreased year-on-year from 2.2 million to 952,000. On the constructive aspect, core income — which doesn’t embrace COVID-19 testing services — grew 110% year-over-year to $56 million, greater than half of whole income. The corporate’s non-GAAP earnings got here in at 32 cents a share, in comparison with $4.05 within the prior 12 months quarter.

In brief, Fulgent has thrived throughout the pandemic, when COVID testing necessities boosted demand, and has seen demand drop sharply because the pandemic subsided. Though this has decreased income, the corporate has two shiny spots to attract on: increasing its core income and money holdings, a legacy of the COVID growth occasions. Fulgent had $918 million in money and liquid property on the finish of Q3 ’22.

Checking in once more with analyst Cooper, we discover that he sees the corporate within the midst of a metamorphosis, from worthwhile COVID testing in a pandemic period to an oncology testing base that may energy future operations.

“With a robust core expertise spine throughout each the Moist Lab and Dry Lab and broader operations, we imagine the corporate can efficiently promote these capabilities in addition to add new clients for every. It’s going to reveal the power to scale with out compromising service (as the corporate prides itself on aggressive turnaround occasions if Pioneer) was not central to the corporate’s success, however with targets that the corporate sees as a complete baseline check of $105 billion, the runway is critical,” Cooper wrote.

“From an funding perspective, $26 in internet money per share not solely helps create a ground for the inventory, however creates an extra choice for capital deployment,” the analyst summarized.

Total, Cooper thinks this can be a inventory price holding. The analyst charges FLGT inventory as an outperformer (i.e. Purchase), and its $45 value goal suggests a robust upside potential of 34%.

Solely 3 analysts have weighed in on FLGT inventory, and their opinions embrace 2 Buys to 1 Maintain for a Reasonable Purchase consensus score. The common inventory value goal of $45 matches Cooper’s. (We see FLGT inventory forecast)

To search out good concepts for shares buying and selling at engaging valuations, go to TipRanks’ Greatest shares to purchasea instrument that unites all of TipRanks’ fairness insights.

Not giving an opinion: The opinions expressed on this article are solely these of the featured analysts. The content material is meant for use for informational functions solely. It is vitally essential to do your personal evaluation earlier than making any funding.

Leave a Comment